REVIVE: Education & Collaboration

Through REVIVE, we are improving, accelerating and streamlining antibiotic research and development. There has been a void in the discovery of antibiotics for more than 20 years, while the abandoning of antibiotic research and development in companies and academic laboratories has led to the risk of valuable knowledge being lost.

To address this challenge, GARDP created REVIVE in 2017. REVIVE is designed to capture old and new knowledge and skills in antimicrobial drug discovery, research and development, as well as to support and connect this community worldwide. With a network of world class experts, REVIVE is an outreach activity to ensure knowledge is shared between clinical as well as academic researchers at various stages of their career.

REVIVE activities

Facilitating learning

With a strong educational focus, REVIVE is gathering, disseminating and increasing knowledge in the field of antimicrobial research and development. Activities include open access webinars, conference sessions and workshops led by experts. Recordings are freely available on the website.

Connecting people

REVIVE facilitates engagement with its network of world class experts from around the world through the ‘talk to an expert’ function, providing upcoming researchers with access to vital information.

Knowledge sharing

Through the Antimicrobial Viewpoints series, we invite experts on different aspects of antimicrobial resistance, discovery, research and development to share their knowledge and opinions on the current status and future challenges of this field. A resources section including an antimicrobial research and development encyclopedia will be launched in the near future which will define many terms across the field.

Download In Focus: External Scientific Affairs and REVIVE


Visit the REVIVE site

We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.